Roche Looks To New CFO Hippe To Help Steel Itself For Restructuring
This article was originally published in The Pink Sheet Daily
Alan Hippe will replace CFO Erich Hunziker as Roche implements its radical cost-cutting plan.
You may also be interested in...
Implementation of Roche's 'Operational Excellence' Initiative Will Trim Nearly 5,000 Sales, Manufacturing and R&D Jobs
Roche characterized the anticipated restructuring plan as a pre-emptive strike and maintained that the integration of Genentech was successful and continuing apace.
Roche confirms suspension of dosing in Phase III taspoglutide program after reporting safety problems in June. But Roche's pain could be a gain for the competing GLP-1 Bydureon from Lilly/Amylin/Alkermes.
The hard task of integration—and the battle to retain Genentech employees—begins, while the DNA ticker symbol is up for grabs.